The Food and Drug Administration has approved the Alzheimer’s drug aducanumab despite controversy over whether there is sufficient evidence to support the drug’s effectiveness.
Aducanumab is the first Alzheimer’s drug approved by the FDA in almost 20 years. It has been developed by the company Biogen in collaboration with a Japanese firm Eisai. It is the first drug approved that aims at a protein called amyloid beta that builds up in the brains of Alzheimer’s patients.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.